NVO
Novo Nordisk A/S
37.50$
+0.6%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +12.1% | -0.8% | +4.1% | +4.8% | +20.2% | -8.9% | -1.6% | -2.4% | +5.6% | +22.3% | -18.9% | – | |
| – | +3.1% | -1.0% | +3.6% | +10.1% | +15.2% | -1.0% | -0.3% | +39.4% | -15.4% | -10.2% | +25.8% | – | |
| – | +13.9% | -0.7% | +4.2% | +3.8% | +21.1% | -10.3% | -1.8% | -10.8% | +12.1% | +30.0% | -26.2% | – | |
| – | +28.7% | -17.7% | +87.8% | -41.3% | +45.5% | -25.3% | +13.4% | +31.7% | -4.8% | -29.8% | +73.0% | – | |
| – | +15.9% | -20.5% | +0.0% | +19.4% | +14.3% | -22.8% | +7.9% | +43.2% | -17.8% | -26.4% | +14.8% | – | |
| – | +31.6% | -18.9% | +35.0% | -17.8% | +37.2% | -26.5% | +15.7% | +9.3% | -3.4% | -26.8% | +45.4% | – | |
| – | -0.5% | +19.0% | -18.6% | +30.4% | +8.6% | +5.6% | -13.8% | -29.2% | +34.0% | +87.9% | -54.6% | – | |
| – | -57.7% | +126.4% | -24.7% | -47.4% | +520.3% | +1.8% | -4.3% | +1.0% | +72.4% | -59.5% | -57.1% | – | |
| – | -1.6% | +15.6% | -20.6% | +35.7% | +3.4% | +4.2% | -8.7% | -24.5% | +34.0% | +81.9% | -56.8% | – | |
| – | +1.3% | +15.1% | -18.9% | +34.1% | +3.4% | +9.2% | -8.7% | -24.5% | +32.4% | +86.7% | -56.8% | – | |
| – | -2.3% | +15.7% | -21.1% | +36.2% | +3.4% | +2.8% | -8.7% | -24.5% | +34.4% | +80.6% | -56.8% | – | |
| – | -13.0% | +29.4% | -3.2% | +4.5% | +22.7% | +0.4% | -5.3% | -23.7% | +19.5% | +74.1% | -44.1% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.